CN102302663B - Chinese medicine for treating primary carcinoma of liver - Google Patents
Chinese medicine for treating primary carcinoma of liver Download PDFInfo
- Publication number
- CN102302663B CN102302663B CN2011102647864A CN201110264786A CN102302663B CN 102302663 B CN102302663 B CN 102302663B CN 2011102647864 A CN2011102647864 A CN 2011102647864A CN 201110264786 A CN201110264786 A CN 201110264786A CN 102302663 B CN102302663 B CN 102302663B
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- liver
- radix
- primary carcinoma
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 40
- 206010073069 Hepatic cancer Diseases 0.000 title 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 title 1
- 238000011282 treatment Methods 0.000 claims abstract description 21
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 12
- 241000208340 Araliaceae Species 0.000 claims abstract description 11
- 241000218176 Corydalis Species 0.000 claims abstract description 11
- 241000180649 Panax notoginseng Species 0.000 claims abstract description 11
- 235000003143 Panax notoginseng Nutrition 0.000 claims abstract description 11
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 11
- 235000008434 ginseng Nutrition 0.000 claims abstract description 11
- 239000002994 raw material Substances 0.000 claims abstract description 5
- 244000153234 Hibiscus abelmoschus Species 0.000 claims description 12
- 241000283956 Manis Species 0.000 claims description 10
- 230000000694 effects Effects 0.000 abstract description 16
- 210000004185 liver Anatomy 0.000 abstract description 8
- 239000000843 powder Substances 0.000 abstract description 6
- 201000009030 Carcinoma Diseases 0.000 abstract description 5
- 239000002775 capsule Substances 0.000 abstract description 5
- 229940079593 drug Drugs 0.000 abstract description 5
- 238000007796 conventional method Methods 0.000 abstract description 3
- 239000006187 pill Substances 0.000 abstract description 3
- 238000002360 preparation method Methods 0.000 abstract description 3
- 230000006872 improvement Effects 0.000 abstract description 2
- 206010004542 Bezoar Diseases 0.000 abstract 1
- 241000402754 Erythranthe moschata Species 0.000 abstract 1
- 241000935235 Fritillaria meleagris Species 0.000 abstract 1
- 240000005373 Panax quinquefolius Species 0.000 abstract 1
- 241000283966 Pholidota <mammal> Species 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 description 15
- 239000008280 blood Substances 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 8
- 230000003203 everyday effect Effects 0.000 description 6
- 206010003445 Ascites Diseases 0.000 description 4
- 230000036528 appetite Effects 0.000 description 4
- 235000019789 appetite Nutrition 0.000 description 4
- 206010023126 Jaundice Diseases 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 201000007270 liver cancer Diseases 0.000 description 3
- 210000003141 lower extremity Anatomy 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 206010022998 Irritability Diseases 0.000 description 2
- 206010027336 Menstruation delayed Diseases 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 206010003178 Arterial thrombosis Diseases 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 206010010075 Coma hepatic Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- 241001672981 Purpura Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 238000010317 ablation therapy Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- BFPSDSIWYFKGBC-UHFFFAOYSA-N chlorotrianisene Chemical compound C1=CC(OC)=CC=C1C(Cl)=C(C=1C=CC(OC)=CC=1)C1=CC=C(OC)C=C1 BFPSDSIWYFKGBC-UHFFFAOYSA-N 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000001723 curing Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000010102 embolization Effects 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 201000001059 hepatic coma Diseases 0.000 description 1
- 208000007386 hepatic encephalopathy Diseases 0.000 description 1
- 210000005161 hepatic lobe Anatomy 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a Chinese medicine for treating primary carcinoma of the liver. By the Chinese medicine, the problems about preparation of a medicament for treating primary carcinoma of the liver, improvement on curative effects and treatment for primary carcinoma of the liver are effectively solved. The technical scheme for solving the problems is that: the Chinese medicine is prepared by mixing raw materials such as 10 to 30g of musk, 25 to 50g of bezoar, 30 to 60g of thunberg fritillary bulb, 30 to 60g of pangolin, 20 to 50g of ginseng, 25 to 60g of American ginseng, 35 to 55g of notoginseng root and 30 to 60g of rhizome corydalis and grinding into powder and can be prepared into capsules or powder or pills by the conventional method. The Chinese medicine has a scientific and reasonable formula, and is easy to prepare, low in cost, good in curative effects and convenient to take, and is an innovation in medicines.
Description
Technical field
The present invention relates to field of medicaments, particularly a kind of Chinese medicine of treating primary hepatocarcinoma.
Background technology
Primary hepatocarcinoma (primary carcinoma of the liver) is one of China's common cancer.Mortality rate is high, in the dead cis-position of malignant tumor, is only second to stomach, esophagus and occupies the 3rd, is partly accounting for second in the geographic rural area, is only second to gastric cancer.China dies from about 110,000 people of hepatocarcinoma every year, accounts for 45% of whole world PLC mortality number.Therefore, strengthen the research of primary hepatocarcinoma treatment, prolong patient's life cycle, improve curative effect, improving patients ' life quality is clinical tumor worker's the task of top priority.The main treatment means of hepatocarcinoma is an excision, and early stage postoperative 1 year, 3 years and 5 years survival rates are respectively 80%--92%, 61%--86% and 41%--75%.But 90% patient loses the surgical engine meeting because of tumor than big or liver cirrhosis; The normal liver cell is responsive to lonizing radiation, and HCC then sensitivity is relatively poor, and need＞4000cGy just possibly obtain certain part control; The local ablation therapy can play effects such as local control tumor, relief of symptoms, and the treatment that can be used as the excision patient that can not undergo surgery is selected, but only effective less than the hepatocarcinoma of 5cm to tumor; All below 20%, curative effect is undesirable to the part remission rate of hepatocarcinoma for chemotherapeutics; Trans-hepatic artery conduit TAE (TACE) or TACE add portal vein embolization (PVE) improves effective percentage; Improvement is also arranged life cycle, but whether complete, best medication combined and best aspects such as thromboembolism type still need further research at arterial thrombosis; The biological targeting treatment all is lower than 10% to the effective percentage of primary hepatocarcinoma.In sum, modern medicine does not still have the good curing method to advanced primary liver cancer.The Chinese medicine advanced primary liver cancer has potential advantages, how to develop Chinese medicine safely and efficiently, improves low treatment present situation of life span weak point, weak curative effect, quality of life, has very important significance.
Summary of the invention
To above-mentioned situation, for overcoming the prior art defective, the purpose of this invention is to provide a kind of Chinese medicine of treating primary hepatocarcinoma, can effectively solve the medicine of preparation treatment primary hepatocarcinoma, improve curative effect, realize treatment problem to primary hepatocarcinoma.
The technical scheme that the present invention solves is; This Chinese medicine is processed as raw material by Moschus 10-30g, Calculus Bovis 25-50g, Bulbus Fritillariae Thunbergii 30-60g, Squama Manis 30-60g, Radix Ginseng 20-50g, Radix Panacis Quinquefolii 25-60g, Radix Notoginseng 35-55g, Rhizoma Corydalis 30-60g; Above-mentioned raw materials is mixed; Be ground into powder, process capsule or powder or pill by conventional method.
Scientific formulation of the present invention, reasonable is prone to produce preparation, and cost is low, good effect, and taking convenience is innovation pharmaceutically.
The specific embodiment
Elaborate below in conjunction with the embodiment specific embodiments of the invention.
The present invention can be provided by following examples in concrete:
Embodiment 1
Chinese medicine of the present invention is made up of Moschus 10g, Calculus Bovis 25g, Bulbus Fritillariae Thunbergii 30g, Squama Manis 30g, Radix Ginseng 20g, Radix Panacis Quinquefolii 25g, Radix Notoginseng 35g, Rhizoma Corydalis 30g.
Embodiment 2
Chinese medicine of the present invention is made up of Moschus 20g, Calculus Bovis 40g, Bulbus Fritillariae Thunbergii 45g, Squama Manis 45g, Radix Ginseng 45g, Radix Panacis Quinquefolii 50g, Radix Notoginseng 40g, Rhizoma Corydalis 45g.
Embodiment 3
Chinese medicine of the present invention is made up of Moschus 30g, Calculus Bovis 50g, Bulbus Fritillariae Thunbergii 60g, Squama Manis 60g, Radix Ginseng 50g, Radix Panacis Quinquefolii 60g, Radix Notoginseng 55g, Rhizoma Corydalis 60g.
Embodiment 4
Chinese medicine of the present invention is made up of Moschus 25g, Calculus Bovis 45g, Bulbus Fritillariae Thunbergii 50g, Squama Manis 50g, Radix Ginseng 40g, Radix Panacis Quinquefolii 30g, Radix Notoginseng 45g, Rhizoma Corydalis 40g.
The method for preparing of the foregoing description 1,2,3,4 is with raw materials mix, is ground into powder, processes capsule or powder or pill by conventional method.
Chinese medicine is thought, hepatocarcinoma ianthone mass in the abdomen) be that multiple factor causes irritability to be lost in bar reaching, qi depression to blood stasis forms.Gas is the power of blood operation, and irritability stasis is not all right, and it is capable to influence blood, i.e. " stagnation of QI is blood clotting then ".So with the passing of time stagnation of liver-QI delays, how can form blood stasis, it is swollen local knot to occur, and Fa is a mass in the abdomen (comprising hepatocarcinoma).To the treatment of this disease, when with circulation of qi promoting, invigorate blood circulation, blood stasis dispelling is main, promotes the passages through which vital energy circulates normal circulation of qi and blood, soften, dwindle, disappear in order to blood stasis dissipation ， mass in the abdomen.Moschus promoting blood circulation to restore menstrual flow, reducing swelling and alleviating pain in the medicine of the present invention, the natural Calculus Bovis clearing away heart-fire detoxification, eliminate phlegm for resuscitation, cool liver endogenous wind stopping, Radix Panacis Quinquefolii boosting qi and nourishing yin, clearing away heat and promoting production of body fluid.All medicines share, and play the merit of activating QI to eliminate phlegm, stasis and resolving masses alive, reducing swelling and alleviating pain, strengthening the body resistance altogether.Modern study finds that the natural Moschus has inhibitory action to human body tumour cell, and the breathing of ehrlich carcinoma, murine sarcoma cell is had inhibitory action.The Borneolum Syntheticum main component is left-handed, dextrorotation or racemization Borneolum Syntheticum, and antiinflammatory, analgesic effect are arranged, and has report to claim to alleviate hepatocarcinoma later stage pain.Above medicine is worked in coordination with compatibility, can produce the effect of dissipate retraction, relief of symptoms to hepatocarcinoma.And, obtained sufficient proof through test, interrelated data is following:
In January, 2007～2008 year June, use medicine treatment Patients with Primary 92 examples of the present invention, establish kind capsule matched group 92 examples at random, observation group's curative effect is superior to matched group.
1 physical data
Through the Patients with Primary of pathology or clinical definite, meet the dialectical standard of traditional Chinese medical science syndrome of qi stagnation and blood stasis, 18～70 years old age, quality of life scoring>60 minutes.As once executed chemotherapy, must end of chemotherapy more than 1 month and have solid tumor or operation to fail excision person.Meet above-mentioned requirements person's 100 examples, be divided into 2 groups at random.Observation group's 92 examples, male 34 examples, women 16 examples; The oldest 70 years old, minimum 29 years old, average 48.6 years old; Matched group 92 examples, male 32 examples, women 18 examples; The oldest 68 years old, minimum 25 years old, average 47.3 years old.
Include standard in: 1. be diagnosed as primary hepatocarcinoma (confirming) and Chinese medical discrimination and belong to syndrome of qi stagnation and blood stasis through histological examination, AFP, imaging examination, and the person more than 3 months that can survive; 2. this medicine of voluntary accepting treatment or finished more than 1 month and the person that still has the solid tumor through radiotherapy, chemotherapy etc., or operations research is failed excision person; 3. 18～70 years old age; 4. liver function is normal basically; 5. the quality of life scoring was 60 fens above persons (karnofsky point system standard); 6. there are not serious jaundice ascites, cachexia, hepatic coma and central nervous system's transferrer.
2 Therapeutic Method
1. observation group: medicine of the present invention, each 1.5g, every day 2 times;
2. matched group: kind capsule, each 5, every day 4 times.
2 months was 1 course of treatment, finished the back check 2 courses of treatment.Inactive other cancer therapy drugs in the course of treatment.
3 criterions of therapeutical effect and result
3.1 criterion of therapeutical effect
According to the solid tumor efficacy assessment standard that WHO formulates, be divided into CR (alleviating fully), PR (part is alleviated), SD (stablizing), PD (progress).CR: tumor disappears and continues more than 1 month; PR: the orthogonal diameter product of two maximums of tumor dwindles more than 50% and continues more than 1 month; SD: the orthogonal diameter product of two maximums of tumor dwindles less than 50%, increases to be no more than 25%, continues more than 1 month; PD: the orthogonal diameter product of two maximums of tumor increases above 25%.
3.2 therapeutic outcome
Two groups of short term effects are relatively seen table 1, and two groups of quality of lifes, AFP and symptom integral are relatively seen table 2.The two groups of curative effects in treatment back compare, and all < 0.05, observation group's curative effect is superior to matched group to the P value.
Table 1 liang group curative effect relativelyExample (%)
| Group | n | CR | PR | SD | PD | Total effective rate |
| Observation group | 92 | 4 | 14 | 50 | 24 | 19.6 |
| Matched group | 92 | 0 | 6 | 30 | 56 | 6.5 |
Table 2 liang group patients ' life quality, AFP and symptom integral are relatively(x ± s)
3.3 model case
On the basis of above-mentioned test, through treatment, the observation to model case, curative effect of medication of the present invention has also obtained proving that fully model case is following:
Lee, the man, 54 years old, people from Zhoukou City, Henan, the primary hepatocarcinoma IV phase, lymphonodi coeliaci shifts, and lung shifts.Jaundice, a large amount of ascites are become thin, and lower limbs edema is weak; The side of body is pain down, and poor appetite is looked into AFP＞1000mg/L, ALB 20.6g/L; About 6cm * the 5cm of CT prompting liver right lower lobe tumor focus maximum diameter, oral medicine of the present invention, each 1.5g, every day 2 times; Symptom obviously alleviates after serveing on February, check AFP 651.3mg/L, ALB 34.7g/L, the about 4cm * 4cm of CT prompting tumor.
History, the woman, 61 years old, people from Nanyang, Henan, the primary hepatocarcinoma I phase, become thin, weak, poor appetite, distending pain in the hypochondrium is uncomfortable, and anemia is looked into RBC 3.0 * 10
12/ L, HGB 85g/L, AFP＞584.2mg/L, the about 1cm * 0.8cm of CT prompting right lobe of liver tumor focus maximum diameter; Oral medicine of the present invention, each 1.5g, every day 2 times, serve on April after remission; The check result of laboratory test is all normal, and CT prompting tumor disappears, and patient's life span is above 4 years.
Huang, the woman, 57 years old, people from Zhengzhou, Henan, primary hepatocarcinoma late period, lymphonodi coeliaci shifts, and lung shifts, anemia, purpura, a large amount of ascites, lower limbs edema, poor appetite is become thin, and looks into RBC 2.7 * 10
12/ L, PLT 36 * 10
9/ L, HGB 62g/L, AFP＞1000mg/L, ALB 22.4g/L; Fill the air occupy-place in the CT prompting liver, the visible a plurality of occupancy tuberositys in abdominal cavity, the maximum 3.2cm * 2.4cm, oral medicine of the present invention; Each 1.5g, every day 2 times, serve on January after symptom obviously alleviate, look into RBC 3.9 * 10
12/ L, PLT 61 * 10
9/ L, HGB 86g/L, AFP＞814.3mg/L, ALB30.9g/L.
Zhang, the man, 70 years old, people from Zhengzhou, Henan, primary hepatocarcinoma late period, lymphonodi coeliaci shifts, and lung shifts; Jaundice, a large amount of ascites are become thin, lower limbs edema, the side of body is pain down, and is weak, poor appetite; Look into TBIL 168.7 μ mol/L, AFP＞1000mg/L, ALB 25.8g/L fills the air occupy-place in the CT prompting liver, the visible a plurality of occupancy tuberositys in abdominal cavity, oral medicine of the present invention; Each 1.5g, every day 2 times, serve on January after symptom obviously alleviate, look into TBIL 73.1 μ mol/L, AFP＞827.7mg/L, ALB 34.1g/L.
Can find out clearly that by above-mentioned data the present invention can produce the effect of dissipate retraction, relief of symptoms to hepatocarcinoma, prolongs patient's life; Alleviate less patient suffering; Be the innovation on the treatment liver-cancer medicine, have actual clinical meaning and exploitation to be worth, economic and social benefit is huge.
Claims (5)
1. a Chinese medicine of treating primary hepatocarcinoma is characterized in that, is processed as raw material by Moschus 10-30g, Calculus Bovis 25-50g, Bulbus Fritillariae Thunbergii 30-60g, Squama Manis 30-60g, Radix Ginseng 20-50g, Radix Panacis Quinquefolii 25-60g, Radix Notoginseng 35-55g, Rhizoma Corydalis 30-60g.
2. the Chinese medicine of treatment primary hepatocarcinoma according to claim 1 is characterized in that, is made up of described Moschus 10g, Calculus Bovis 25g, Bulbus Fritillariae Thunbergii 30g, Squama Manis 30g, Radix Ginseng 20g, Radix Panacis Quinquefolii 25g, Radix Notoginseng 35g, Rhizoma Corydalis 30g.
3. the Chinese medicine of treatment primary hepatocarcinoma according to claim 1 is characterized in that, is made up of described Moschus 20g, Calculus Bovis 40g, Bulbus Fritillariae Thunbergii 45g, Squama Manis 45g, Radix Ginseng 45g, Radix Panacis Quinquefolii 50g, Radix Notoginseng 40g, Rhizoma Corydalis 45g.
4. the Chinese medicine of treatment primary hepatocarcinoma according to claim 1 is characterized in that, is made up of described Moschus 30g, Calculus Bovis 50g, Bulbus Fritillariae Thunbergii 60g, Squama Manis 60g, Radix Ginseng 50g, Radix Panacis Quinquefolii 60g, Radix Notoginseng 55g, Rhizoma Corydalis 60g.
5. the Chinese medicine of treatment primary hepatocarcinoma according to claim 1 is characterized in that, is made up of described Moschus 25g, Calculus Bovis 45g, Bulbus Fritillariae Thunbergii 50g, Squama Manis 50g, Radix Ginseng 40g, Radix Panacis Quinquefolii 30g, Radix Notoginseng 45g, Rhizoma Corydalis 40g.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011102647864A CN102302663B (en) | 2011-09-08 | 2011-09-08 | Chinese medicine for treating primary carcinoma of liver |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011102647864A CN102302663B (en) | 2011-09-08 | 2011-09-08 | Chinese medicine for treating primary carcinoma of liver |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102302663A CN102302663A (en) | 2012-01-04 |
| CN102302663B true CN102302663B (en) | 2012-12-26 |
Family
ID=45376645
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011102647864A Expired - Fee Related CN102302663B (en) | 2011-09-08 | 2011-09-08 | Chinese medicine for treating primary carcinoma of liver |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102302663B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109010586A (en) * | 2018-10-25 | 2018-12-18 | 林洪生 | It is a kind of for controlling the Chinese medicine composition and preparation method of tumour growth |
| CN114949022B (en) * | 2022-06-06 | 2023-05-05 | 尚药局(宁夏)制药有限公司 | Traditional Chinese medicine composition for treating tumors |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1493322A (en) * | 2002-11-01 | 2004-05-05 | 刘连春 | Chinese medicine composition for treating tumour |
| CN101698038B (en) * | 2009-10-23 | 2011-04-27 | 王令喜 | Paster for treating cancer pain and preparation method thereof |
-
2011
- 2011-09-08 CN CN2011102647864A patent/CN102302663B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1493322A (en) * | 2002-11-01 | 2004-05-05 | 刘连春 | Chinese medicine composition for treating tumour |
| CN101698038B (en) * | 2009-10-23 | 2011-04-27 | 王令喜 | Paster for treating cancer pain and preparation method thereof |
Non-Patent Citations (4)
| Title |
|---|
| 中医药治疗原发性肝癌的现状与展望;彭海燕等,1;《中西医结合肝病杂志》;20060628;第16卷(第03期);184-187 * |
| 原发性肝癌中医辨治法则初探;吴国水,1;《实用中医内科杂志》;20061205;第20卷(第06期);608 * |
| 吴国水,1.原发性肝癌中医辨治法则初探.《实用中医内科杂志》.2006,第20卷(第06期), |
| 彭海燕等,1.中医药治疗原发性肝癌的现状与展望.《中西医结合肝病杂志》.2006,第16卷(第03期), |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102302663A (en) | 2012-01-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101745065B (en) | Pharmaceutical composition with effects of resisting cancer and alleviating pain | |
| CN103041312A (en) | Traditional Chinese medicine composition with antineoplastic effect and preparation method and application thereof | |
| CN104523865B (en) | Medicine for treating breast diseases | |
| CN101711848B (en) | Chinese medicinal composition capable of adjunctively treating tumour | |
| CN101301352A (en) | Chinese medicinal preparation for treating cancer and preparation | |
| CN103877377A (en) | Chinese medicament preparation for treating lymphoma and preparation method of Chinese medicament preparation | |
| CN102671135A (en) | Chinese medicinal composition for treating ovarian cyst, and preparation method thereof | |
| CN102688317A (en) | Traditional Chinese medicine for treating liver cancer | |
| CN102302663B (en) | Chinese medicine for treating primary carcinoma of liver | |
| CN104758844A (en) | Traditional Chinese medicine for treating premature ovarian failure | |
| CN102973892A (en) | Traditional Chinese medicine combination for treating breast cancer | |
| CN102755600A (en) | Traditional Chinese medicine compound for resisting breast cancer metastasis and reoccurrence | |
| CN102743455B (en) | Chinese patent medicine for treating diabetes mellitus | |
| CN101549025B (en) | Traditional Chinese medicine for treating cancer | |
| CN101612358B (en) | Anticancer dispersing paste and preparation method thereof | |
| CN104922456A (en) | Traditional Chinese medicine composition for treating anemia after tumor chemotherapy | |
| CN102716381B (en) | Traditional Chinese medicine used for treating appendicitis | |
| CN102205067B (en) | Traditional Chinese medicine composition for treating chronic urticaria | |
| CN101919967B (en) | Traditional Chinese drug for treating esophagus cancer | |
| CN101288758B (en) | Analgesic medicine | |
| CN103272123B (en) | Chinese herbal preparation for treating rectum carcinoma and preparation method thereof | |
| CN103800561A (en) | Traditional Chinese medicine for treating renal hematuria | |
| CN103316299B (en) | Chinese medicine composition for treating primary liver cancer | |
| CN105726849B (en) | It is a kind of for treating the Chinese medicine of diabetes Depression | |
| CN105213998A (en) | A kind of Chinese medicine composition of combined with chemotherapy treatment nonsmall-cell lung cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20121226 |